Natera · 2 weeks ago
Vice President/Sr. Director, Head of GU Oncology Lifecycle Management
United States
Full-time
Hybrid
Director/Executive
$233K/yr - $291K/yr
8+ years expNatera is a global leader in cell-free DNA testing focused on changing the management of disease in reproductive health, oncology, and organ transplantation. As the Head of GU Oncology Lifecycle Management, you will shape the vision and strategy for Natera’s oncology product portfolio in GU cancers, driving a cohesive, cross-functional approach to address critical unmet needs in cancer care.
BiotechnologyGeneticsHealth DiagnosticsMedicalWomen's
Responsibilities
Own the lifecycle planning and success of GU cancers, collaborating with cross-functional teams to develop and execute a strategic plan that drives usage, awareness, and advocacy across key stakeholders worldwide
Expand Signatera access across GU tumors – prioritize key indications, own evidence roadmaps, close evidence gaps and submit for coverage
Establish tumor-specific goals to be owned by the lifecycle team and across functions
Serve as a critical member on clinical / medical teams, helping define and prioritize key indications while identifying and addressing evidence gaps
Monitor performance & mitigate risks – In close partnership with Marketing team, track performance and deliver against GU commercial and medical goals, identifying potential issues / risks and implement mitigation strategies
Serve as a critical member on commercial subteams, helping to maximize Natera potential by escalating and addressing critical barriers that limit commercial adoption
Maintain a deep expertise in the GU cancers space by integrating real-time customer insights, publications, data presentations, competitive and market intelligence
Shape the value proposition for Natera’s oncology products in collaboration with Medical Affairs and Commercial Marketing, leveraging clinical evidence and market dynamics
Regularly present strategic plans and progress to executive leadership
Qualification
Required
Bachelor's degree, Advanced degree preferred (MBA or PhD)
GU oncology market experience strongly preferred
8-10 years experience in product marketing, market analytics at a pharmaceutical / biotech company
Previous KOL management experience preferred
Working knowledge of oncology molecular testing / biomarkers
~25% travel required (advisory boards, congresses, sales / marketing meetings, customer meetings)
Ability to lead without authority, influence and inspire individuals
Proven strategic agility with an enterprise mindset and ability to operate with executive presence
Ability to partner and collaborate across a broad range of internal and external partners
Strong customer orientation and focus, particularly establishing thought leader relationships
Proven ability to communicate the complex simply (biomarkers, multiple indications, etc.)
Strong organizational / time management skills; manage and complete multiple projects
Preferred
Advanced degree preferred (MBA or PhD)
GU oncology market experience strongly preferred
Previous KOL management experience preferred
Benefits
Comprehensive medical, dental, vision, life and disability plans for eligible employees and their dependents
Free testing in addition to fertility care benefits
Pregnancy and baby bonding leave
401k benefits
Commuter benefits
Generous employee referral program
Company
Natera
Natera specializes in cell-free DNA testing to provide a more targeted interventions to oncology, women's health, and organ health.
5001-10000 employees
H1B Sponsorship
Natera has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (90)
2024 (72)
2023 (37)
2022 (71)
2021 (64)
2020 (40)
Funding
Current Stage
Public CompanyTotal Funding
$1.16BKey Investors
Sofinnova InvestmentsLightspeed Venture PartnersSequoia Capital
2023-09-07Post Ipo Equity· $250M
2022-11-15Post Ipo Equity· $400.05M
2022-03-16Post Ipo Equity· $5M
Leadership Team
Steve Chapman
CEO
Jonathan Sheena
Co-Founder, Board Member
Recent News
2026-01-22
Business Wire
2026-01-22
Yahoo Finance
2026-01-20
Company data provided by crunchbase